Literature DB >> 1619024

Abnormal overnight dexamethasone suppression test in subjects receiving rifampicin therapy.

V Kyriazopoulou1, A G Vagenakis.   

Abstract

We have studied the effects of rifampicin on the overnight 1-mg dexamethasone suppression test usually employed to exclude suspected Cushing's syndrome. Previous observations indicate that in humans, rifampicin profoundly attenuates the biological effects of hydrocortisol and prednisolone, probably by increasing the metabolism of these drugs in the liver. The study was carried out in 16 normal volunteers. All subjects had a normal overnight 1-mg dexamethasone suppression test (468 +/- 86 vs. 32 +/- 21 nmol/L; mean +/- SD). In 8 subjects treated with rifampicin (600 mg) for 10 days, the inhibitory effect of dexamethasone on serum cortisol was completely prevented (575 +/- 114 vs. 434 +/- 82). In the remaining 8 rifampicin-treated subjects, the inhibitory effect of 1, 2, or 3 mg dexamethasone on serum cortisol was not observed. When 4 mg dexamethasone were administered, the serum cortisol level was 193 nmol/L, above the expected normal suppression value. The plasma dexamethasone concentration was very low after rifampicin treatment (range, 1.2-4.8 nmol/L). We conclude that when patients are treated with rifampicin, the standard overnight dexamethasone suppression test not only has no diagnostic value, but can be very misleading.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1619024     DOI: 10.1210/jcem.75.1.1619024

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

1.  Carbamazepine and false positive dexamethasone suppression tests for Cushing's syndrome.

Authors:  Ronald C W Ma; Wing Bun Chan; Wing Yee So; Peter C Y Tong; Juliana C N Chan; Chun Chung Chow
Journal:  BMJ       Date:  2005-02-05

2.  The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.

Authors:  Lynnette K Nieman; Beverly M K Biller; James W Findling; John Newell-Price; Martin O Savage; Paul M Stewart; Victor M Montori
Journal:  J Clin Endocrinol Metab       Date:  2008-03-11       Impact factor: 5.958

Review 3.  Drugs and HPA axis.

Authors:  Alberto Giacinto Ambrogio; Francesca Pecori Giraldi; Francesco Cavagnini
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

Review 4.  Cushing's syndrome: update on signs, symptoms and biochemical screening.

Authors:  Lynnette K Nieman
Journal:  Eur J Endocrinol       Date:  2015-07-08       Impact factor: 6.664

5.  The effects of therapy with rifampicin and isoniazid on basic investigations for Cushing's syndrome.

Authors:  T H Zawawi; M S al-Hadramy; S M Abdelwahab
Journal:  Ir J Med Sci       Date:  1996 Oct-Dec       Impact factor: 1.568

Review 6.  The diagnosis of Cushing's syndrome.

Authors:  Ty B Carroll; James W Findling
Journal:  Rev Endocr Metab Disord       Date:  2010-06       Impact factor: 6.514

Review 7.  Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes.

Authors:  Hongbing Wang; Edward L LeCluyse
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

8.  SXR, a novel steroid and xenobiotic-sensing nuclear receptor.

Authors:  B Blumberg; W Sabbagh; H Juguilon; J Bolado; C M van Meter; E S Ong; R M Evans
Journal:  Genes Dev       Date:  1998-10-15       Impact factor: 11.361

9.  Activation of steroid and xenobiotic receptor (SXR, NR1I2) and its orthologs in laboratory, toxicologic, and genome model species.

Authors:  Matthew R Milnes; Adriana Garcia; Emily Grossman; Felix Grün; Jason Shiotsugu; Michelle M Tabb; Yukio Kawashima; Yoshinao Katsu; Hajime Watanabe; Taisen Iguchi; Bruce Blumberg
Journal:  Environ Health Perspect       Date:  2008-07       Impact factor: 9.031

10.  Abnormal Dexamethasone Suppression Tests in a Rifapentine-Treated Patient With Primary Aldosteronism.

Authors:  Hongman Wang; Ying Song; Zhixin Xu; Ying Jing; Wenwen He; Zhengping Feng; Qifu Li; Shumin Yang
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-04       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.